Multicenter, Prospective Study for Urinary Exosomal Biomarkers of Kidney

Status Recruiting

Clinical Trial Summary

The investigators aim to identify urinary exosomal biomarkers that represent the extent of graft fibrosis from deceased donor kidney transplantation. Urinary samples will be collected from deceased kidney donors at the time of procurement and zero-day kidney graft biopsy will be performed at the time of transplant. The association between urinary exosomes and the degree of graft fibrosis will be analyzed to identify biomarkers that represent fibrosis. The correlation between these biomarkers and graft long term outcomes will be investigated.

Clinical Trial Description

Interstitial fibrosis and tubular atrophy (IFTA), previously known as chronic allograft nephropathy (CAN), is diagnosed by pathologic changes involving all parts of the renal parenchyma and is one of the factors impacting graft survival and outcome. Currently, there is no standard to predict allograft fibrosis status at the time of procurement. Noninvasive biomarkers are necessary to monitor allograft status and to predict long-term outcomes.

The investigators aim to conduct a multicenter prospective study to identify urinary exosomal biomarkers that represent the extent of graft fibrosis from deceased donor kidney transplantation. Urinary samples will be collected from deceased kidney donors at the time of procurement and zero-day kidney graft biopsy will be performed at the time of transplant. The zero-day biopsy tissue will be stained with Masson's Trichrome staining, Collagen I, III, IV immunostaining to evaluate the degree of fibrosis. Also, by ultracentrifuge, we will extract urinary exosomes and perform proteomics analysis and RNA-sequencing. The association between urinary exosomes and the degree of graft fibrosis will be analyzed to identify biomarkers that represent fibrosis. The correlation between these biomarkers and graft long term outcomes will be investigated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03870542
Study type	Observational
Source	Asan Medical Center
Contact	Sung Shin, MD, PhD
Phone	82-2-3010-3964
Email	sshin@amc.seoul.kr
Status	Recruiting
Phase
Start date	May 11, 2019
Completion date	April 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04560582` - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Withdrawn	`NCT04216303` - Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus
Recruiting	`NCT03689075` - Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation	Phase 4
Recruiting	`NCT05788276` - Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?	Phase 4
Active, not recruiting	`NCT04882254` - Normothermic Machine Perfusion: an Additional Value for Kidney Transplant Outcomes?	Phase 2
Completed	`NCT04918199` - Human Versus Computer-based Predictions of Long Allograft Survival
Active, not recruiting	`NCT04897438` - Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection	N/A
Enrolling by invitation	`NCT05285878` - Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation	Phase 2
Recruiting	`NCT04226859` - Trajectories of Glomerular Filtration Rate and Progression to End Stage Renal Disease After Kidney Transplantation
Recruiting	`NCT06056518` - Investigating the Impact of AI on Shared Decision Making in Post-kidney Transplant Care	N/A
Completed	`NCT05619679` - A Clinical Practice Snapshot on Pediatric Kidney Transplantation
Completed	`NCT06020534` - Aortoiliac Stenosis in Kidney Transplantation
Active, not recruiting	`NCT02960802` - Kidney Transplantation and Renal and Myocardial Perfusion	N/A
Completed	`NCT05200949` - SURGICAL EXPERIENCE ON RENAL TRANSPLANT COMPLICATIONS
Completed	`NCT04258891` - Multidimensional System to Dynamically Predict Graft Survival After Kidney Transplantation
Recruiting	`NCT06186843` - Plant-based Diet for Kidney Transplant Recipients	N/A
Active, not recruiting	`NCT04154267` - Protocol Biopsies in High-risk Renal Transplant Recipients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Multicenter, Prospective Study for Urinary Exosomal Biomarkers of Kidney Allograft Tubulointerstitial Fibrosis — UFO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms